{"pmid":32220930,"title":"Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.","text":["Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.","Clin J Am Soc Nephrol","Sparks, Matthew A","South, Andrew","Welling, Paul","Luther, J Matt","Cohen, Jordana","Byrd, James Brian","Burrell, Louise M","Batlle, Daniel","Tomlinson, Laurie","Bhalla, Vivek","Rheault, Michelle N","Soler, Maria Jose","Swaminathan, Sundar","Hiremath, Swapnil","32220930"],"journal":"Clin J Am Soc Nephrol","authors":["Sparks, Matthew A","South, Andrew","Welling, Paul","Luther, J Matt","Cohen, Jordana","Byrd, James Brian","Burrell, Louise M","Batlle, Daniel","Tomlinson, Laurie","Bhalla, Vivek","Rheault, Michelle N","Soler, Maria Jose","Swaminathan, Sundar","Hiremath, Swapnil"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220930","week":"202014|Mar 30 - Apr 05","doi":"10.2215/CJN.03530320","keywords":["ACE inhibitors","Angiotensin-Converting Enzyme Inhibitors","COVID-19","Renin-Angiotensin System","angiotensin","hypertension","renin angiotensin system","severe acute respiratory syndrome coronavirus 2","virology"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1662624089127256064,"score":7.2532344,"similar":[{"pmid":32203970,"title":"Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade.","text":["Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade.","Here, we review the most recent findings on the effects of SARS-CoV-2 infection on kidney diseases, including acute kidney injury, and examine the potential effects of ARBs on the outcomes of patients with COVID-19. Lastly, we discuss the clinical management of COVID-19 patients with existing chronic renal disorders, particularly those in dialysis and with kidney transplants.","Nephron","Perico, Luca","Benigni, Ariela","Remuzzi, Giuseppe","32203970"],"abstract":["Here, we review the most recent findings on the effects of SARS-CoV-2 infection on kidney diseases, including acute kidney injury, and examine the potential effects of ARBs on the outcomes of patients with COVID-19. Lastly, we discuss the clinical management of COVID-19 patients with existing chronic renal disorders, particularly those in dialysis and with kidney transplants."],"journal":"Nephron","authors":["Perico, Luca","Benigni, Ariela","Remuzzi, Giuseppe"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32203970","week":"202013|Mar 23 - Mar 29","doi":"10.1159/000507305","keywords":["Angiotensin receptor blockers","Angiotensin-converting enzyme inhibitors","COVID-19","Renal and cardiac side effects","SARS-CoV-2","Severe acute respiratory syndrome coronavirus"],"source":"PubMed","topics":["Mechanism","Transmission","Treatment"],"weight":1,"_version_":1662334543311405057,"score":57.512745},{"pmid":32061198,"title":"[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].","text":["[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].","The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality.","Zhonghua Jie He He Hu Xi Za Zhi","Sun, M L","Yang, J M","Sun, Y P","Su, G H","32061198"],"abstract":["The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Sun, M L","Yang, J M","Sun, Y P","Su, G H"],"date":"2020-02-16T11:00:00Z","year":2020,"_id":"32061198","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0014","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1662334544464838656,"score":56.71467},{"pmid":32215613,"title":"Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for Epidemiologic Investigations.","text":["Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for Epidemiologic Investigations.","Mortality from coronavirus disease 2019 (COVID-19) is strongly associated with cardiovascular disease, diabetes, and hypertension. These disorders share underlying pathophysiology related to the renin-angiotensin system (RAS) that may be clinically insightful. In particular, activity of the angiotensin-converting enzyme 2 (ACE2) is dysregulated in cardiovascular disease, and this enzyme is used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to initiate the infection. Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart. Conversely, mechanistic evidence from related coronaviruses suggests that SARS-CoV-2 infection may downregulate ACE2, leading to toxic overaccumulation of Angiotensin II that induces acute respiratory distress syndrome and fulminant myocarditis. RAS inhibition could mitigate this effect. With conflicting mechanistic evidence, we propose key clinical research priorities necessary to clarify the role of RAS inhibition in COVID-19 mortality that could be rapidly addressed by the international research community.","Clin Infect Dis","Hanff, Thomas C","Harhay, Michael O","Brown, Tyler S","Cohen, Jordana B","Mohareb, Amir M","32215613"],"abstract":["Mortality from coronavirus disease 2019 (COVID-19) is strongly associated with cardiovascular disease, diabetes, and hypertension. These disorders share underlying pathophysiology related to the renin-angiotensin system (RAS) that may be clinically insightful. In particular, activity of the angiotensin-converting enzyme 2 (ACE2) is dysregulated in cardiovascular disease, and this enzyme is used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to initiate the infection. Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart. Conversely, mechanistic evidence from related coronaviruses suggests that SARS-CoV-2 infection may downregulate ACE2, leading to toxic overaccumulation of Angiotensin II that induces acute respiratory distress syndrome and fulminant myocarditis. RAS inhibition could mitigate this effect. With conflicting mechanistic evidence, we propose key clinical research priorities necessary to clarify the role of RAS inhibition in COVID-19 mortality that could be rapidly addressed by the international research community."],"journal":"Clin Infect Dis","authors":["Hanff, Thomas C","Harhay, Michael O","Brown, Tyler S","Cohen, Jordana B","Mohareb, Amir M"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32215613","week":"202013|Mar 23 - Mar 29","doi":"10.1093/cid/ciaa329","keywords":["Angiotensin-Converting Enzyme 2","COVID-19","Cardiovascular Disease","Renin-Angiotensin System","SARS-CoV-2"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1662445896416100352,"score":56.66496},{"pmid":32118642,"title":"Science in the fight against the novel coronavirus disease.","text":["Science in the fight against the novel coronavirus disease.","Chin Med J (Engl)","Wang, Jian-Wei","Cao, Bin","Wang, Chen","32118642"],"journal":"Chin Med J (Engl)","authors":["Wang, Jian-Wei","Cao, Bin","Wang, Chen"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32118642","week":"202010|Mar 02 - Mar 08","doi":"10.1097/CM9.0000000000000777","source":"PubMed","topics":["Diagnosis","Treatment","Mechanism"],"weight":1,"_version_":1662334544090497025,"score":47.02774},{"pmid":32162995,"title":"Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine.","text":["Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine.","The epidemic of coronavirus disease 2019 (COVID-19), originating in Wuhan, China, has become a major public health challenge for not only China but also countries around the world. The World Health Organization announced that the outbreaks of the novel coronavirus have constituted a public health emergency of international concern. As of February 26, 2020, COVID-19 has been recognized in 34 countries, with a total of 80,239 laboratory-confirmed cases and 2,700 deaths. Infection control measures are necessary to prevent the virus from further spreading and to help control the epidemic situation. Due to the characteristics of dental settings, the risk of cross infection can be high between patients and dental practitioners. For dental practices and hospitals in areas that are (potentially) affected with COVID-19, strict and effective infection control protocols are urgently needed. This article, based on our experience and relevant guidelines and research, introduces essential knowledge about COVID-19 and nosocomial infection in dental settings and provides recommended management protocols for dental practitioners and students in (potentially) affected areas.","J Dent Res","Meng, L","Hua, F","Bian, Z","32162995"],"abstract":["The epidemic of coronavirus disease 2019 (COVID-19), originating in Wuhan, China, has become a major public health challenge for not only China but also countries around the world. The World Health Organization announced that the outbreaks of the novel coronavirus have constituted a public health emergency of international concern. As of February 26, 2020, COVID-19 has been recognized in 34 countries, with a total of 80,239 laboratory-confirmed cases and 2,700 deaths. Infection control measures are necessary to prevent the virus from further spreading and to help control the epidemic situation. Due to the characteristics of dental settings, the risk of cross infection can be high between patients and dental practitioners. For dental practices and hospitals in areas that are (potentially) affected with COVID-19, strict and effective infection control protocols are urgently needed. This article, based on our experience and relevant guidelines and research, introduces essential knowledge about COVID-19 and nosocomial infection in dental settings and provides recommended management protocols for dental practitioners and students in (potentially) affected areas."],"journal":"J Dent Res","authors":["Meng, L","Hua, F","Bian, Z"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32162995","week":"202011|Mar 09 - Mar 15","doi":"10.1177/0022034520914246","keywords":["dental education","dental practice management","dental public health","infection control","transmission","virology"],"source":"PubMed","locations":["China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1662334543763341312,"score":44.327892}]}